Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma | MicrobiomeTrials← Back to trialsNCT06858501
Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma
WITHDRAWNPHASE2INTERVENTIONAL
Trial Details
Start: 2026-09-22Est. Completion: 2028-12-20
Enrollment target: 0 participants Other microbiome trials you might be interested in
Ganglioneuroblastoma, NodularNeuroblastoma
This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care su…
Birmingham, United StatesEst. completion Dec 31, 2029
Recurrent GanglioneuroblastomaRecurrent NeuroblastomaRefractory GanglioneuroblastomaRefractory Neuroblastoma
This phase I/II trial studies the side effects and best dose of iberdomide when given together with chemoimmunotherapy d…
Oakland, United States
Est. completion Sep 30, 2029
GanglioneuroblastomaLocalized Resectable NeuroblastomaLocalized Unresectable NeuroblastomaNeuroblastoma
This phase III trial studies how well response and biology-based risk factor-guided therapy works in treating younger pa…
Birmingham, United StatesEst. completion Sep 30, 2026